This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should First Trust NASDAQ100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal
by Zacks Equity Research
Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $378.90 in the latest trading session, marking a -1.38% move from the prior day.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Ziopharm (ZIOP) Down on Workforce Reduction Announcement
by Zacks Equity Research
Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.
Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA
by Zacks Equity Research
Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.
Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data
by Zacks Equity Research
Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.
Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies
by Zacks Equity Research
Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.
Stock Market News for Sep 27, 2021
by Zacks Equity Research
After a roller coaster ride, the Dow and the S&P 500 closed in the green on Friday. However, China's move to ban cryptocurrencies weighed on the technology sector pushing the Nasdaq to close in the red.
AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space
by Zacks Equity Research
AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing
by Zacks Equity Research
On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility
Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only
by Zacks Equity Research
The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
by Zacks Equity Research
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
by Ekta Bagri
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
The Zacks Analyst Blog Highlights: Moderna, Quanta Services, Avantor, ON Semiconductor and KLA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Quanta Services, Avantor, ON Semiconductor and KLA
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $440.72, marking a +1.54% move from the previous day.
J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection
by Zacks Equity Research
J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.
Top 5 High-Flying Stocks That Have Survived September Mayhem
by Nalak Das
We have narrowed down our search to five large-cap stocks that have gained nearly 5% or more than 5% month to date. These are: AVTR, PWR, ON, KLAC, and MRNA.
Fed's FOMC Meeting in Focus
by Zacks Equity Research
Fed's FOMC Meeting in Focus.
Housing Data Better than Expected on Growth in Northeast
by Mark Vickery
Housing Starts came in at 1.62 million, higher than the 1.55 million estimate, which happened to be the headline number for July.
Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
by Kinjel Shah
Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.